Diabetes

Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA-DC  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 25/February/2019, 1.03 am
Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA-DC  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 25/February/2019, 1.03 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Ribonucleic acid-based therapy for autoimmune diabetes (TIDM): LncRNA CACS15 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 25/February/2019, 12.51 am
Ribonucleic acid-based therapy for autoimmune diabetes (TIDM): LncRNA CACS15 increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 25/February/2019, 12.51 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of…

read more

Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA CCAT2  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 24/February/2019, 11.25 pm
Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA CCAT2  augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 24/February/2019, 11.25 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Ribonucleic acid-based therapy for glucose homeostasis and TIIDM:  LncRNA PCGEM1 increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM, via down regulation of its target gene, 22/February/2019, 11.35 pm
Ribonucleic acid-based therapy for glucose homeostasis and TIIDM:  LncRNA PCGEM1 increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM, via down regulation of its target gene, 22/February/2019, 11.35 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel shows that…

read more

Molecular therapy for diabetes: Teneligliptin (brand name: Tenilia), a DPP-4 (a dipeptidyl peptidase-4) inhibitor used in the treatment of hyperglycemia,  increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 22/February/2019, 10.22 pm
Molecular therapy for diabetes: Teneligliptin (brand name: Tenilia), a DPP-4 (a dipeptidyl peptidase-4) inhibitor used in the treatment of hyperglycemia,  increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 22/February/2019, 10.22 pm 960 720 Dr Boomi's Genom-2-Discovery Center

 Introduction: What they say:   A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study…

read more

Ribonucleic acid-based therapy for diabetes: LncRNA UCA1  increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 22/February/2019, 9.32 pm
Ribonucleic acid-based therapy for diabetes: LncRNA UCA1  increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 22/February/2019, 9.32 pm 960 720 Dr Boomi's Genom-2-Discovery Center

 Introduction: What they say:   A study from the Stem Cell Transplantation Program, Division of Pediatric Hematology/Oncology, Boston Children’s Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA shows that “The Lin28/let-7 axis regulates glucose metabolism.” This study…

read more
Start Typing